EP0547544B1
(de)
*
|
1991-12-18 |
1997-03-12 |
Hoechst Aktiengesellschaft |
Verfahren zur Gewinnung von insulinhaltigen Lösungen
|
ATE203998T1
(de)
*
|
1993-04-27 |
2001-08-15 |
Hoechst Ag |
Amorphe monosphärische formen von insulinderivaten
|
DE19512484A1
(de)
|
1995-04-04 |
1996-10-17 |
Bayer Ag |
Kohlenhydratmodifizierte Cytostatika
|
ATE264871T1
(de)
*
|
1996-07-26 |
2004-05-15 |
Aventis Pharma Gmbh |
Insulinderivate mit erhöhter zinkbindung
|
DE19652713C2
(de)
*
|
1996-12-18 |
2001-11-22 |
Aventis Pharma Gmbh |
Verfahren zur Reinigung von Insulin und Insulinderivaten durch Chromatographie an stark saurem Kationenaustauscher
|
CA2306877A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Eli Lilly And Company |
Insoluble insulin compositions
|
US6444641B1
(en)
|
1997-10-24 |
2002-09-03 |
Eli Lilly Company |
Fatty acid-acylated insulin analogs
|
DE19825447A1
(de)
|
1998-06-06 |
1999-12-09 |
Hoechst Marion Roussel De Gmbh |
Neue Insulinanaloga mit erhöhter Zinkbildung
|
DE19838097A1
(de)
|
1998-08-24 |
2000-03-02 |
Hoechst Marion Roussel De Gmbh |
Verfahren zur chromatographischen Reinigung von Insulinen
|
US6933272B1
(en)
|
1998-09-22 |
2005-08-23 |
Erik Helmerhorst |
Use of non-peptidyl compounds for the treatment of insulin related ailments
|
WO2001072323A2
(en)
*
|
2000-03-24 |
2001-10-04 |
Genentech, Inc. |
Use of insulin for the treatment of cartilagenous disorders
|
US7316999B2
(en)
|
2000-06-02 |
2008-01-08 |
Novo Nordisk A/S |
Glucose dependent release of insulin from glucose sensing insulin derivatives
|
DE10114178A1
(de)
|
2001-03-23 |
2002-10-10 |
Aventis Pharma Gmbh |
Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
|
FR2822834B1
(fr)
*
|
2001-04-02 |
2005-02-25 |
Flamel Tech Sa |
Suspension colloidale de nanoparticules a base de copolymeres amphiphile pour la vectorisation de principes actifs et leur mode de preparation
|
WO2003020201A2
(en)
*
|
2001-08-28 |
2003-03-13 |
Eli Lilly And Company |
Pre-mixes of glp-1 and basal insulin
|
EP2243776A1
(en)
|
2001-10-12 |
2010-10-27 |
High Point Pharmaceuticals, LLC |
Substituted piperidines and their use for the treatment of diseases related to the histamine H3 receptor
|
US7179788B2
(en)
*
|
2001-10-19 |
2007-02-20 |
Eli Lilly And Company |
Biphasic mixtures of GLP-1 and insulin
|
CZ2004710A3
(cs)
*
|
2001-12-20 |
2005-02-16 |
Eli Lilly And Company |
Inzulínová sloučenina s protrahovaným účinkem
|
US7774816B2
(en)
*
|
2002-04-23 |
2010-08-10 |
Rovi Technologies Corporation |
Conflict manager for a video recorder
|
DE10227232A1
(de)
|
2002-06-18 |
2004-01-15 |
Aventis Pharma Deutschland Gmbh |
Saure Insulinzubereitungen mit verbesserter Stabilität
|
FR2843117B1
(fr)
*
|
2002-07-30 |
2004-10-15 |
Flamel Tech Sa |
Polyaminoacides fonctionnalises par au moins un groupement hydrophobe et leurs applications notamment therapeutiques
|
US20040138099A1
(en)
*
|
2002-11-29 |
2004-07-15 |
Draeger Eberhard Kurt |
Insulin administration regimens for the treatment of subjects with diabetes
|
EP1615698B1
(en)
|
2003-04-11 |
2010-09-29 |
High Point Pharmaceuticals, LLC |
New amide derivatives and pharmaceutical use thereof
|
BRPI0409600A
(pt)
*
|
2003-04-29 |
2006-04-18 |
Lilly Co Eli |
análogo de insulina, composição, método de tratamento de hiperglicemia, e, análogo de pró-insulina
|
FR2860516B1
(fr)
*
|
2003-10-03 |
2006-01-13 |
Flamel Tech Sa |
Homopolyaminoacides telecheliques fonctionnalises par des groupements hydrophobes et leurs applications notamment therapeutiques
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
FR2862536B1
(fr)
*
|
2003-11-21 |
2007-11-23 |
Flamel Tech Sa |
Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
|
FR2873040B1
(fr)
|
2004-07-19 |
2007-11-30 |
Flamel Technologies Sa |
Formulation colloidale d'insuline longue action et sa preparation
|
US7833513B2
(en)
|
2004-12-03 |
2010-11-16 |
Rhode Island Hospital |
Treatment of Alzheimer's Disease
|
CN103110635A
(zh)
|
2005-07-04 |
2013-05-22 |
海波因特制药有限责任公司 |
组胺h3受体拮抗剂
|
WO2007015805A1
(en)
|
2005-07-20 |
2007-02-08 |
Eli Lilly And Company |
1-amino linked compounds
|
JP5198280B2
(ja)
|
2005-11-17 |
2013-05-15 |
イーライ リリー アンド カンパニー |
グルカゴン受容体アンタゴニスト、並びにその調製及び治療への使用
|
FR2896164B1
(fr)
*
|
2006-01-18 |
2008-07-04 |
Flamel Technologies Sa |
Formulation colloidale d'insuline longue action et sa preparation
|
EP2241327A1
(en)
|
2006-03-15 |
2010-10-20 |
Novo Nordisk A/S |
Mixtures of Amylin and Insulin
|
JP2009531376A
(ja)
|
2006-03-28 |
2009-09-03 |
ハイ ポイント ファーマシューティカルズ,リミティド ライアビリティ カンパニー |
ヒスタミンh3受容体活性を有するベンゾチアゾール
|
EA016415B1
(ru)
|
2006-04-24 |
2012-04-30 |
Эли Лилли Энд Компани |
Ингибиторы 11-бета-гидроксистероид-дегидрогеназы типа 1
|
NZ571972A
(en)
|
2006-05-29 |
2011-09-30 |
High Point Pharmaceuticals Llc |
3- (1, 3-benz0di0x0l-5-yl) -6- (4-cyclopropylpiperazin-1-yl) -pyridazine, its salts and solvates and its use as histamine h3 receptor antagonist
|
DE102006031962A1
(de)
*
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
DE102006031955A1
(de)
*
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
|
US7417517B2
(en)
*
|
2006-07-13 |
2008-08-26 |
Motorola, Inc. |
Method and apparatus for a communications filter
|
JP2011504871A
(ja)
|
2007-06-01 |
2011-02-17 |
ノボ・ノルデイスク・エー/エス |
固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト
|
EP2164458A1
(en)
|
2007-06-01 |
2010-03-24 |
Novo Nordisk A/S |
Stable non-aqueous pharmaceutical compositions
|
ES2558930T3
(es)
|
2007-08-13 |
2016-02-09 |
Novo Nordisk A/S |
Análogos de la insulina de acción rápida
|
JP5241849B2
(ja)
|
2007-11-16 |
2013-07-17 |
ノボ・ノルデイスク・エー/エス |
インスリン及びインスリン分泌性ペプチドを含む薬学的組成物
|
RU2524423C2
(ru)
|
2008-01-09 |
2014-07-27 |
Санофи-Авентис Дойчланд Гмбх |
Новые производные инсулина с чрезвычайно замедленным профилем время/действие
|
NZ586589A
(en)
|
2008-01-09 |
2012-04-27 |
Sanofi Aventis Deutschland |
Novel insulin analogues having an extremely delayed time-action profile
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
PL219335B1
(pl)
*
|
2008-07-04 |
2015-04-30 |
Inst Biotechnologii I Antybiotyków |
Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
ES2650621T3
(es)
|
2008-10-17 |
2018-01-19 |
Sanofi-Aventis Deutschland Gmbh |
Combinación de una insulina y un agonista de GLP-1
|
KR20110088575A
(ko)
|
2008-11-21 |
2011-08-03 |
하이 포인트 파마슈티칼스, 엘엘씨 |
아다만틸 벤즈아미드 화합물
|
CN107080836A
(zh)
|
2009-07-06 |
2017-08-22 |
赛诺菲-安万特德国有限公司 |
含有甲硫氨酸的水性胰岛素制备物
|
JP2012532177A
(ja)
*
|
2009-07-06 |
2012-12-13 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
熱及び振動安定性インスリン製剤
|
WO2011003823A1
(de)
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Langsamwirkende insulinzubereitungen
|
MX2012001399A
(es)
|
2009-07-31 |
2012-03-21 |
Sanofi Aventis Deutschland |
Profarmacos que comprenden un conjugado de insulina-conector.
|
SG178195A1
(en)
|
2009-07-31 |
2012-03-29 |
Sanofi Aventis Deutschland |
Long acting insulin composition
|
PE20121362A1
(es)
|
2009-11-13 |
2012-10-17 |
Sanofi Aventis Deutschland |
Composicion farmaceutica que comprende despro36exendina-4(1-39)-lys6-nh2, insulina gly(a21)-arg(b31)-arg(b32) y metionina
|
TWI468171B
(zh)
|
2009-11-13 |
2015-01-11 |
Sanofi Aventis Deutschland |
含glp-1激動劑及甲硫胺酸之醫藥組成物
|
AU2011202239C1
(en)
*
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
RU2546520C2
(ru)
|
2010-08-30 |
2015-04-10 |
Санофи-Авентис Дойчланд Гмбх |
Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
|
EP2438930A1
(en)
|
2010-09-17 |
2012-04-11 |
Sanofi-Aventis Deutschland GmbH |
Prodrugs comprising an exendin linker conjugate
|
AU2012208349A1
(en)
|
2011-01-20 |
2013-07-18 |
Zealand Pharma A/S |
Combination of acylated glucagon analogues with insulin analogues
|
EP2670368A4
(en)
|
2011-02-03 |
2015-04-15 |
Pharmedica Ltd |
NEW ORAL DISSOLUTION FILMS FOR INSULIN DELIVERY FOR THE TREATMENT OF DIABETES
|
CN102219851B
(zh)
|
2011-05-09 |
2012-05-30 |
甘李药业有限公司 |
甘精胰岛素结晶的制备方法
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
CA2843586A1
(fr)
|
2011-08-10 |
2013-02-14 |
Adocia |
Solution injectable d'au moins une insuline basale
|
CN103917241A
(zh)
|
2011-08-29 |
2014-07-09 |
赛诺菲-安万特德国有限公司 |
用于2型糖尿病患者中的血糖控制的药物组合
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
EP2771296B1
(en)
|
2011-10-25 |
2017-09-27 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
CN104114155B
(zh)
|
2012-01-09 |
2019-02-15 |
阿道恰公司 |
Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
|
PL222975B1
(pl)
|
2012-05-23 |
2016-09-30 |
Inst Biotechnologii I Antybiotyków |
Analog insuliny lub jego farmaceutycznie dopuszczalna sól, kompozycja farmaceutyczna o przedłużonym działaniu terapeutycznym oraz zastosowanie analogu insuliny
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
DK2854841T3
(en)
|
2012-06-04 |
2017-05-22 |
Diamedica Inc |
Kallikrein-1-glycosylation isoforms of human tissue
|
FR3001896B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
|
US20150314003A2
(en)
|
2012-08-09 |
2015-11-05 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
|
FR3001895B1
(fr)
|
2013-02-12 |
2015-07-03 |
Adocia |
Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
|
US9707275B2
(en)
*
|
2012-12-19 |
2017-07-18 |
Wockhardt Limited |
Stable aqueous composition comprising human insulin or an analogue or derivative thereof
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
|
HUE042381T2
(hu)
|
2013-04-03 |
2019-06-28 |
Sanofi Sa |
Cukorbetegség kezelése hosszan ható inzulinkészítményekkel
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
RU2016132342A
(ru)
|
2014-01-09 |
2018-02-14 |
Санофи |
Стабилизированные фармацевтические составы на основе инсулиновых аналогов и/или инсулиновых производных
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
MX2016008978A
(es)
|
2014-01-09 |
2016-10-04 |
Sanofi Sa |
Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
|
RS64300B1
(sr)
|
2014-12-12 |
2023-07-31 |
Sanofi Aventis Deutschland |
Formulacija fiksnog odnosa insulin glargina/liksisenatida
|
CN104688677B
(zh)
*
|
2015-02-05 |
2018-02-09 |
通化东宝药业股份有限公司 |
一种稳定的甘精胰岛素注射液及其制备方法
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患治療
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第2型糖尿病病患之治療
|
AR107560A1
(es)
|
2016-02-24 |
2018-05-09 |
Lilly Co Eli |
Compuesto que disminuye la glucosa en la sangre
|
FR3052072A1
(fr)
|
2016-06-07 |
2017-12-08 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
BR112019011394A2
(pt)
|
2016-12-05 |
2019-12-10 |
Nuritas Ltd |
composições compreendendo peptídeo wkdeagkplvk
|
EP3329930A1
(en)
|
2016-12-05 |
2018-06-06 |
Nuritas Limited |
Pharmaceuctical compositions
|
CN110446501A
(zh)
|
2017-03-09 |
2019-11-12 |
代阿麦迪卡股份有限公司 |
组织激肽释放酶1的剂型
|
FR3070264A1
(fr)
|
2017-08-24 |
2019-03-01 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris de 5,8 a 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
EP3720472A1
(fr)
|
2017-12-06 |
2020-10-14 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
FR3083089A1
(fr)
|
2018-06-29 |
2020-01-03 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
FR3083088B1
(fr)
|
2018-06-29 |
2020-10-02 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
JP2021505607A
(ja)
|
2017-12-07 |
2021-02-18 |
アドシア |
5.8〜8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液
|
WO2019110773A1
(fr)
|
2017-12-07 |
2019-06-13 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
CN111836616B
(zh)
|
2017-12-07 |
2024-01-16 |
阿道恰公司 |
包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph 7为7的可注射溶液
|
KR20210005630A
(ko)
*
|
2018-04-16 |
2021-01-14 |
유니버시티 오브 유타 리서치 파운데이션 |
글루코스-반응성 인슐린
|
WO2019243628A1
(fr)
|
2018-06-22 |
2019-12-26 |
Adocia |
Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
|
FR3084585B1
(fr)
|
2018-08-03 |
2020-11-06 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un compose amphiphile porteur de radicaux hydrophobes
|
KR20200017078A
(ko)
|
2018-08-08 |
2020-02-18 |
주식회사 대웅제약 |
지속형 인슐린 아날로그 및 그 복합체
|
WO2020115334A1
(fr)
|
2018-12-07 |
2020-06-11 |
Adocia |
Procede de preparation d'une composition stable sous forme d'une solution aqueuse injectable
|
US20200179489A1
(en)
|
2018-12-07 |
2020-06-11 |
Adocia |
Injectable solution at ph 7 comprising at least one basal insulin which pi is from 5.8 to 8.5 and a co-polyamino-acid bearing carboxylate charges and hydrophobic radicals and a limited amount of m-cresol
|
KR20200080748A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법
|
KR20200080747A
(ko)
|
2018-12-27 |
2020-07-07 |
주식회사 폴루스 |
인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법
|
KR20200082618A
(ko)
|
2018-12-31 |
2020-07-08 |
주식회사 폴루스 |
인슐린 과발현용 램프 태그 및 이를 이용한 인슐린의 제조방법
|
WO2020245470A1
(fr)
|
2019-06-07 |
2020-12-10 |
Adocia |
Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5, du liraglutide et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
TW202120536A
(zh)
|
2019-07-31 |
2021-06-01 |
美商美國禮來大藥廠 |
鬆弛素(relaxin)類似物及其使用方法
|
CN113105536B
(zh)
|
2020-09-11 |
2023-07-18 |
美药星(南京)制药有限公司 |
一种新甘精胰岛素原及其制备甘精胰岛素的方法
|
CN114805610B
(zh)
*
|
2022-06-23 |
2022-10-04 |
北京惠之衡生物科技有限公司 |
一种高表达甘精胰岛素前体的重组基因工程菌及其构建方法
|